Point72 Asset Management
STOK icon

Point72 Asset Management’s Stoke Therapeutics STOK Stock Holding History

Point72 Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,222,213
Closed -$38.8M – 4462
2025
Q4 		$38.8M Sell
1,222,213
-84,485
-6% -$2.54M 0.04% 521
2025
Q3 		$30.7M Buy
+1,306,698
New +$22.4M 0.05% 399
2024
Q2 		– Sell
-142,458
Closed -$1.92M – 2419
2024
Q1 		$1.92M Buy
+142,458
New +$863K ﹤0.01% 1277
2023
Q2 		– Sell
-9,409
Closed -$78.4K – 2756
2023
Q1 		$78.4K Sell
9,409
-19,291
-67% -$174K ﹤0.01% 1683
2022
Q4 		$265K Buy
+28,700
New +$298K ﹤0.01% 1226
2022
Q1 		– Sell
-233,997
Closed -$5.61M – 1383
2021
Q4 		$5.61M Buy
+233,997
New +$5.58M 0.02% 642
2020
Q4 		– Sell
-39,244
Closed -$1.31M – 1122
2020
Q3 		$1.31M Buy
+39,244
New +$1.12M 0.01% 749

Other funds holding STOK

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Point72 Asset Management's STOK Position: Q1 2026 in Review

Point72 Asset Management sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 1,222,213 shares — an estimated $38.8M sold.

Point72 Asset Management first reported a position in STOK in Q3 2020 and held it in 7 quarters. The position peaked at $38.8M in Q4 2025. 198 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Point72 Asset Management reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,222,213 Stoke Therapeutics shares in Q1 2026, an estimated $38.8M.
  • Point72 Asset Management first reported a position in Stoke Therapeutics in Q3 2020 and held it in 7 quarters.
  • Point72 Asset Management's Stoke Therapeutics position peaked at $38.8M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.